The concepts of harmfulness and therapeutic efficacy can only be examined in relation to each other and have only a relative significance depending on the progress of scientific knowledge and the use for which the medicinal product is intended. The particulars and documents which must accompany an application for marketing authorization for a medicinal product demonstrate that potential risks are outweighed by the therapeutic efficacy of the product.
Recital 7, Directive (EU) 2001/83
Judgment of the Court (Fourth Chamber), 10 July 2014. Markus D. and G.Decision
Recital 7 in the preamble to Directive 2001/83 is worded as follows: ‘The concepts of harmfulness and therapeutic efficacy can be examined only in relation to one another and have only a relative significance, depending on the progress …
10 Jul 2014 · 62013CJ0358
Opinion of Mr Advocate General Geelhoed delivered on 3 February 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/Decision
This leads me to give the following answer to the question posed: The pharmacological effect of a product is one of the factors that must be investigated in assessing whether a product has a significant influence on the metabolism and can …
3 Feb 2005 · 62003CC0211
Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision
In the third place, according to recital 7 of Directive 2001/83, ‘the concepts of harmfulness and therapeutic efficacy can only be examined in relation to each other and have only a relative significance depending on the progress of …
5 May 2021 · 62018TJ0611
Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision
In that regard, it must be stated that a medicinal product’s SmPC cannot but be interpreted strictly. Before granting an MA, including in the context of the variation or extension of an existing MA, the competent authority must ensure, …
23 Sep 2020 · 62019TJ0549
Judgment of the Court (Second Chamber) of 13 October 2022. M2Beauté Cosmetics GmbH v Bundesrepublik Deutschland.Decision
Recitals 2 and 7 of Directive 2001/83 are worded as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. … The concepts of harmfulness and …
13 Oct 2022 · 62020CJ0616
Opinion of Advocate General Jääskinen delivered on 29 September 2011. European Commission v Republic of Poland.Decision
More precisely, the aim of the marketing authorisation requirement in Article 6(1) of Directive 2001/83 is to guarantee that the potential risks of products are outweighed by their therapeutic efficacy, which is assessed on the basis of …
29 Sep 2011 · 62010CC0185
Judgment of the General Court (Fifth Chamber, Extended Composition) of 15 May 2024. Fresenius Kabi Austria GmbH and Others v European CommisDecision
Secondly, the argument based on recital 7 of Directive 2001/83 is irrelevant, since that recital refers to the original text of Directive 2001/83, including Article 116 thereof, which did not provide for the alternative on which the …
15 May 2024 · 62022TJ0416
Opinion of Advocate General Sharpston delivered on 30 May 2013. Laboratoires Lyocentre v Lääkealan turvallisuus- ja kehittämiskeskus and SosDecision
The present wording of that provision is based on the amendment by Directive 2004/27. [Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to …
30 May 2013 · 62012CC0109
Opinion of Advocate General Ćapeta delivered on 7 April 2022. M2Beauté Cosmetics GmbH v Bundesrepublik Deutschland.Decision
In respect of risks and benefits to health in relation to medicinal products, the recitals state further: The concepts of harmfulness and therapeutic efficacy can only be examined in relation to each other and have only a relative …
7 Apr 2022 · 62020CC0616